What is Neurotechnology?

The broad category of technologies that interface with, monitor, or modulate the nervous system, encompassing brain-computer interfaces, neuromodulation devices, neuroimaging systems, and neuropharmacological tools.

What category does Neurotechnology belong to in BCI?

Neurotechnology is a Core Concepts concept in brain-computer interface science.

Neurotechnology — BCI Glossary

Neurotechnology refers to any technology designed to understand, interact with, or influence the nervous system. The term is intentionally broad, covering everything from basic neuroimaging tools (MRI, PET) to therapeutic devices (deep brain stimulators, cochlear implants) to advanced brain-computer interfaces. In the investment and industry context, "neurotech" has become the standard shorthand for the sector of companies building neural interface devices.

Scope of Neurotechnology

The neurotechnology landscape spans several major categories:

Recording and monitoring: EEG headsets, intracortical electrode arrays, ECoG grids, functional near-infrared spectroscopy (fNIRS), magnetoencephalography (MEG). These technologies capture neural activity for diagnosis, research, or BCI control.
Stimulation and modulation: Deep brain stimulation (DBS), transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), focused ultrasound, responsive neurostimulation (RNS). These technologies deliver energy to neural tissue to treat conditions like Parkinson's disease, epilepsy, and depression.
Brain-computer interfaces: The subset of neurotechnology that establishes bidirectional communication between the brain and external devices — the primary focus of bciintel.com.
Neuroimaging: MRI, fMRI, PET, CT, and other imaging modalities used to visualize brain structure and function.
Neuropharmacology: Drug delivery systems targeted at neural tissue, including intrathecal pumps and localized drug-eluting implants.

Market and Industry

The neurotechnology market encompasses established medical device companies (Medtronic, Abbott, Boston Scientific) with large DBS and neuromodulation businesses alongside venture-backed startups focused on next-generation BCIs (Neuralink, Synchron, Precision Neuroscience, Paradromics). The global neurotechnology market was estimated at over $15 billion in 2024, with the BCI segment representing a rapidly growing but still small fraction of the total.

Regulatory Landscape

Neurotechnology devices are regulated as medical devices by the FDA (in the US), CE marking bodies (in the EU), and equivalent agencies worldwide. The regulatory pathway depends on the device class and intended use — ranging from 510(k) clearance for non-invasive EEG systems to premarket approval (PMA) for implanted neurostimulators. The FDA's Breakthrough Device Designation has been granted to several BCI companies, accelerating their regulatory timelines.

Ethical Considerations

Neurotechnology raises unique ethical questions about cognitive liberty, mental privacy, and informed consent. As BCIs become capable of decoding speech, emotion, and cognitive states, the field faces growing scrutiny from ethicists, regulators, and the public regarding data ownership, neural data privacy, and the potential for misuse.